Ligand Pharmaceuticals Incorporated | Business Contracts

Severance Agreement, effective December 5, 2022, by and between Ligand Pharmaceuticals Incorporated and Todd C. Davis (Filed With SEC on February 28, 2023)

Director Compensation and Stock Ownership Policy, as amended and restated, effective April 13, 2020 (Filed With SEC on February 28, 2023)

Amended and Restated Employee Matters Agreement, dated as of August 18, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. (f/k/a OmniAb, Inc.),... (Filed With SEC on November 8, 2022)

Tax Matters Agreement, dated as of November 1, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. and OmniAb, Inc (Filed With SEC on November 4, 2022)

Lease, dated June 8, 2021, between the Company and Emery Station Office II, LLC (Filed With SEC on February 28, 2022)

Supply agreement, dated December 22, 2015, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc (Filed With SEC on February 24, 2021)

Commercial License Agreement between Taurus Biosciences, LLC and Minotaur Therapeutics, Inc., dated September 9, 2020 (Filed With SEC on September 10, 2020)

Separation Agreement , effective December 12, 2022, by and between Ligand Pharmaceuticals Incorporated and John Higgins (Filed With SEC on February 28, 2023)

Amended and Restated Severance Plan, effective November 1, 2022 (Filed With SEC on February 28, 2023)

Form of Stock Option Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Form of Performance-Based Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan (Filed With SEC on August 9, 2022)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 28, 2022)

2002 Stock Incentive Plan (as amended and restated effective December 15, 2020) (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Barclays Bank PLC (Filed With SEC on February 24, 2021)

Description of Registered Securities (Filed With SEC on February 24, 2021)

Amendment to Supply Agreement, dated September 21, 2020, by and between Cydex Pharmaceuticals, Inc. and Gilead Sciences, Inc., which amends that certain Supply Agreement, dated... (Filed With SEC on November 6, 2020)

Contingent Value Rights Agreement, dated as of September 30, 2020, by and between Ligand Pharmaceuticals Incorporated and American Stock Transfer & Trust Company, LLC (Filed With SEC on November 6, 2020)

Contingent Value Rights Agreement between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members Representative (regarding Taurus Biosciences, LLC acquisition), dated... (Filed With SEC on September 10, 2020)

Agreement and Plan of Merger among Ligand Pharmaceuticals Incorporated, Taurus Biosciences, LLC and other persons, dated September 9, 2020 (Filed With SEC on September 10, 2020)

Agreement and Plan of Merger among Ligand Pharmaceuticals Incorporated, xCella Biosciences, Inc. and other persons, dated September 8, 2020 (Filed With SEC on September 10, 2020)

Agreement and Plan of Merger, dated as of August 10, 2020, by and among Pfenex, Inc., Ligand Pharmaceuticals Incorporated and Pelican Acquisition Sub, Inc (Filed With SEC on August 11, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Barclays Bank PLC (Filed With SEC on May 8, 2020)

Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among the Registrant, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera... (Filed With SEC on May 8, 2020)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 27, 2020)

Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019 (Filed With SEC on February 27, 2020)

Description of Registered Securities (Filed With SEC on February 27, 2020)

Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc. and Acrotech Biopharma LLC (as successor-in-interest to Spectrum... (Filed With SEC on August 8, 2019)

Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Finance Trust (Filed With SEC on March 5, 2019)

Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc (Filed With SEC on February 28, 2019)

Ligand Pharmaceuticals Incorporated (35)